Targeting a

Fuller Life

Rain Oncology researches, develops and translates innovative targeted cancer therapies for patients

Rain oncology is focused on patients struggling with difficult cancers, and we help provide them hope to get their lives back.

Scientific programs

Rain’s programs  target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit.

MilademetaN

Rain’s lead drug candidate, milademetan, is an oral small molecule, inhibitor of mouse double minute 2 (MDM2). It is in clinical development  in patients with liposarcoma and other MDM2 - dependent cancers.

Resources & Publications

Rain in the News

Rain Oncology Announces Oral Presentation at the 2023 ESMO Sarcoma and Rare Cancers Annual Congress
March 21, 2023 5:50 AM
NEWARK, Calif., March 21, 2023 -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced an abstract accepted as a proffered paper presentation at the 2023 ESMO Sarcoma and Rare Cancers Annual Congress in Lugano, Switzerland.
Rain Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress
March 9, 2023 1:05 PM
NEWARK, Calif., March 9, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with its product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today reports financial results for the fourth quarter and full year ended December 31, 2022, along with an update on the Company's key corporate highlights and upcoming milestones.
Rain Oncology to Present At Oppenheimer 33rd Annual Healthcare Conference
March 7, 2023 8:00 AM
NEWARK, Calif., March 7, 2023 -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that Avanish Vellanki, Chief Executive Officer of Rain, will be presenting a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023, at 11:20 a.m. ET, in a virtual format.